Skip to main content

Health condition · Clinically reviewed

Ewing sarcoma, an aggressive bone cancer of the young that a specialist team can cure.

Defined by the EWSR1-FLI1 fusion and treated with combination chemotherapy, surgery and radiotherapy at specialist UK sarcoma centres. Early referral matters.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a UK sarcoma clinician before publication.

  • 02

    Sourced from guidance

    Checked against NHS England commissioned sarcoma pathways, NICE and international EURO EWING and COG trial protocols.

  • 03

    Current for 2026

    Reflects modern UK practice including VDC/IE chemotherapy, proton beam selection and molecular profiling of the EWSR1-FLI1 fusion.

Key facts

Ewing sarcoma at a glance.

The essentials, in plain English. What it is, who it affects, and how UK sarcoma services treat it today.

  • What it is

    An aggressive small round blue cell sarcoma of bone and soft tissue, defined by a FET-ETS fusion oncogene, most often EWSR1-FLI1.

  • Who gets it

    Second most common bone cancer in children and young adults, with a peak between 10 and 20 years and a slight male predominance.

  • Molecular hallmark

    Around 85 per cent carry the EWSR1-FLI1 fusion. EWSR1-ERG and other fusion partners account for most of the rest.

  • Where it starts

    Pelvis is the commonest primary site, followed by femur, humerus, ribs, spine and tibia. Soft-tissue variants also occur.

  • Spread at diagnosis

    About one in four patients have metastatic disease at diagnosis, most often in the lungs, other bones or bone marrow.

  • Where it is treated

    Only in NHS England commissioned sarcoma and paediatric and AYA oncology centres, with mandatory specialist MDT review.

Why this guide matters

Rare, aggressive, and curable when handled early.

Ewing sarcoma is uncommon, but the pattern is recognisable. Getting to a specialist centre quickly changes what treatment can offer.

  • A molecular disease

    Around 85 per cent of tumours carry an EWSR1-FLI1 fusion. Testing for it confirms the diagnosis and guides trials.

  • Only at specialist centres

    Biopsy and treatment happen at NHS England commissioned sarcoma and paediatric or AYA oncology units, never locally.

  • A whole-team approach

    Chemotherapy, surgery, radiotherapy, proton beam and stem cell transplant are combined in one carefully sequenced plan.

How the diagnosis is made

From first bone pain to a molecular diagnosis.

The pathway a UK sarcoma team will normally follow, in order, so you know what to expect and why each step is done at a specialist centre.

  1. 01

    Recognising

    Persistent bone pain and swelling

    Deep bone pain that is worse at night, is not clearly linked to injury and is joined by a mass or swelling is the classic presentation, not growing pains.

  2. 02

    Recognising

    Plain X-ray of the affected area

    Look for a lytic moth-eaten lesion, periosteal onion-peel reaction, cortical destruction and an associated soft-tissue mass. Any of these needs urgent sarcoma referral.

  3. 03

    Recognising

    Urgent referral to a sarcoma centre

    Suspected primary bone sarcoma is only worked up at a specialist commissioned centre. Biopsy in a non-specialist unit can compromise later limb-sparing surgery.

  4. 04

    Staging

    MRI of the whole bone

    MRI defines the tumour, marrow involvement, skip lesions and the relationship to nerves and vessels. It is the anatomic foundation for surgery and radiotherapy planning.

  5. 05

    Staging

    CT chest, PET-CT and bone marrow

    CT chest looks for lung metastases, whole-body PET-CT stages bone and nodal disease and bilateral bone marrow sampling completes the staging picture.

  6. 06

    Staging

    Image-guided core biopsy

    A specialist sarcoma radiologist plans the tract so it can be excised at surgery. Fresh tissue is sent for pathology and molecular testing.

  7. 07

    Confirming

    Sarcoma pathology and molecular fusion

    Diagnosis needs CD99, FLI1 and NKX2.2 immunohistochemistry with FISH or RT-PCR confirmation of an EWSR1-FLI1 or variant FET-ETS fusion.

Typical timeline: urgent X-ray, sarcoma centre referral and staged workup within a few weeks.

Symptoms

How Ewing sarcoma presents.

A mix of local bone symptoms, systemic upset and sometimes complications like fracture or cord compression. Symptoms depend on where the tumour starts.

  • Localised bone pain

    Deep aching pain over pelvis, femur, humerus, ribs or spine that is worse at night and not fully explained by injury or exercise.

  • Firm swelling or a lump

    A palpable mass over the bone or in the surrounding soft tissue that is fixed, tender and slowly enlarging.

  • Systemic upset

    Low-grade fever, weight loss, fatigue and anaemia can mimic infection and delay the diagnosis.

  • Pathological fracture

    A break through what looks like a lytic lesion on X-ray after minimal or no trauma should never be dismissed as simple.

  • Spinal cord or nerve pressure

    Vertebral or paraspinal disease can cause back pain, radicular symptoms or weakness. Cord compression is a neurosurgical emergency.

  • Chest wall Askin tumour

    Ewing sarcoma of the chest wall may present with rib pain, breathlessness or a pleural effusion.

  • Mistaken for growing pains

    Persistent well-localised bone pain in a young person, especially with swelling or night pain, is not growing pains and needs an X-ray.

  • Red flag - unwell young adult

    Any teenager or young adult with unexplained persistent bone pain, systemic symptoms or a pathological fracture needs urgent sarcoma review.

Treatment

How Ewing sarcoma is treated in the UK.

A carefully sequenced multi-modal programme, delivered only at NHS England commissioned sarcoma and paediatric or AYA oncology centres.

  • Neoadjuvant chemotherapy (VDC/IE)

    Alternating vincristine, doxorubicin and cyclophosphamide with ifosfamide and etoposide on COG AEWS or EURO EWING protocols. The backbone of curative treatment.

  • Local control surgery

    Limb-sparing wide excision at a specialist sarcoma centre, with reconstruction planned by orthopaedic oncology and plastic surgery. See /treatments/plastic-surgery-reconstruction/.

  • Definitive radiotherapy

    Used when surgery would leave unacceptable morbidity or is not possible, or in combination with surgery for close margins or poor histological response.

  • Proton beam therapy

    Selective for young patients and axial tumours where organs at risk are close. Delivered in NHS England commissioned centres. See /treatments/proton-beam-therapy/.

  • Adjuvant chemotherapy

    Completes the total 14 to 18 cycle programme after local control, with cumulative doses tracked to protect the heart and fertility.

  • High-dose chemotherapy with stem cell rescue

    Considered for selected high-risk or poorly responding disease within specialist commissioned services. See /treatments/stem-cell-transplant/.

  • Relapsed and refractory options

    Irinotecan and temozolomide (IT), cabozantinib, regorafenib and lenvatinib are used within trials. EWSR1-FLI1 targeted agents such as TK216 are in development.

  • Molecular profiling

    Tumour molecular profiling confirms the fusion, guides trial eligibility and looks for actionable secondary alterations. See /treatments/tumour-molecular-profiling/.

What this guide is based on

The sources behind every claim on this page.

UK national guidance, specialist commissioned service specifications and international sarcoma trial protocols, current at the time of last review.

Key references

Guidelines and protocols we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your sarcoma team knows the details of your tumour and staging and can tell you how these principles apply to your care.

  • NHS England. Service specification for sarcoma and paediatric and AYA oncology commissioned services.

  • Children’s Cancer and Leukaemia Group (CCLG). Ewing sarcoma treatment guidance.

  • EURO EWING 2012 and iEuroEwing consortium trial protocols.

  • Children’s Oncology Group (COG) AEWS0031 and AEWS1031 protocols.

  • ESMO EURACAN GENTURIS clinical practice guideline for bone sarcomas.

  • Sarcoma UK, Bone Cancer Research Trust and Teenage Cancer Trust patient information.

Red flags

When to act urgently.

Ewing sarcoma is a specialist condition from the moment it is suspected. These situations, at diagnosis or during treatment, need immediate senior review.

  • Suspected pathological fracture

    A fracture through an apparently abnormal bone after low-energy trauma must be treated as a tumour until proven otherwise, and biopsied at a sarcoma centre.

  • Spinal cord compression

    New back pain with leg weakness, saddle numbness or bladder or bowel disturbance in a young patient is an emergency needing urgent MRI and specialist review.

  • Rapidly enlarging mass

    A soft-tissue or bone lump that grows over weeks, especially if larger than five centimetres, deep or painful, must not be observed in primary care.

  • Persistent night pain and B symptoms

    Bone pain that wakes a child or young adult from sleep, with weight loss, sweats or fever, deserves prompt imaging and blood tests.

  • Neutropenic sepsis on chemotherapy

    Fever above 38 degrees during chemotherapy needs immediate assessment in the treating centre. Sepsis can develop within hours.

  • Anthracycline cardiotoxicity

    Breathlessness, ankle swelling or reduced exercise tolerance during or after doxorubicin needs echocardiography and cardio-oncology input.

  • Late relapse in survivorship

    Recurrence can occur many years after treatment. New bone pain or breathlessness in a survivor is investigated urgently.

  • Secondary malignancy

    Radiotherapy and alkylating chemotherapy carry a small long-term risk of second cancers, particularly leukaemia and radiation-associated sarcoma.

Living with it

A long treatment, and long-term care beyond it.

Curative treatment takes around a year. Life after treatment involves surveillance and late-effects care that continues into adulthood.

A quiet reminder

You are not alone in this.

Sarcoma UK, Bone Cancer Research Trust, Teenage Cancer Trust and CCLG offer age-appropriate support to patients, siblings and parents.

  1. 01 Team

    Stay under the specialist centre

    Curative treatment is delivered only at commissioned sarcoma and paediatric or AYA oncology units with dedicated psychosocial and rehabilitation teams.

  2. 02 Fertility

    Fertility conversations early

    Alkylating chemotherapy affects fertility. Sperm banking, oocyte or ovarian tissue preservation are discussed before treatment starts wherever possible.

  3. 03 Late effects

    Long-term survivorship follow-up

    Cardiac, endocrine, growth, hearing and psychological monitoring continues for decades. Late-effects clinics coordinate this care.

  4. 04 Support

    Peer support really matters

    Sarcoma UK, Bone Cancer Research Trust and Teenage Cancer Trust offer age-appropriate support, financial guidance and peer networks for patients and families.

Frequently asked

Everything we get asked about Ewing sarcoma.

Quick answers on molecular testing, chemotherapy, surgery, radiotherapy and prognosis.

  • What is Ewing sarcoma?

    Ewing sarcoma is an aggressive small round blue cell cancer that most often starts in bone but can also arise in soft tissue. It is defined at the molecular level by a fusion between the EWSR1 gene and an ETS family partner, most commonly FLI1. It is the second most common primary bone cancer in children and young adults.

  • Who is most likely to develop it?

    It has a clear peak in the second decade of life, most cases arising between the ages of 10 and 20, and is slightly more common in males than females. It occurs across all ethnic groups but is more frequent in populations of European ancestry. It is not thought to be inherited in the way BRCA-related cancers are.

  • How is the diagnosis confirmed?

    Diagnosis needs specialist sarcoma pathology on a core biopsy taken at a sarcoma centre. The tumour shows characteristic small round blue cell morphology with strong CD99 membrane staining, plus FLI1 and NKX2.2 on immunohistochemistry. Molecular testing using FISH or RT-PCR then confirms an EWSR1-FLI1 or variant FET-ETS fusion.

  • What does treatment involve?

    Treatment is multi-modal and takes around 10 to 12 months. It starts with intensive chemotherapy such as alternating VDC and IE for around six cycles, followed by local control with surgery, radiotherapy or both, and then completion of the full 14 to 18 cycle chemotherapy programme. Proton beam therapy and high-dose chemotherapy with stem cell rescue are used in selected cases.

  • How is it treated on the NHS?

    Ewing sarcoma is a specialist commissioned pathway in NHS England. Care is coordinated by a bone sarcoma MDT and delivered in centres such as the Royal Marsden, University College London Hospitals, Birmingham Children’s Hospital, the Christie and the Great North Children’s Hospital, with proton beam therapy at UCLH and the Christie.

  • What is the outlook?

    For localised disease, current UK and international protocols achieve long-term survival in around 65 to 75 per cent of patients. Metastatic disease at diagnosis, especially with bone or bone marrow involvement, carries a lower cure rate but selected patients still achieve durable remissions. Your specialist team will discuss the outlook in the context of your own tumour and response to treatment.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.